OKUR
OnKure Therapeutics, Inc.
NASDAQ: OKUR · HEALTHCARE · BIOTECHNOLOGY
$2.41
+4.78% today
Updated 2026-10-09
Market cap
$97.35M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.20
Dividend yield
—
52W range
$2 – $5
Volume
0.3M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-1.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →274 stocks currently score above 75
Price targets
Analyst target
$15.50
+543.15%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -1.25 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-10.36M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-29.51M | $-35.31M | $-52.67M | $-59.52M | $-15.35M |
| EPS | — | — | — | — | $-3.20 |
| Free cash flow | $-28.09M | $-34.79M | $-51.17M | $-51.87M | $-10.36M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
OnKure Therapeutics, Inc. trades at $2.41. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -1.25, it sits in the distress.
Frequently asked questions
What is OnKure Therapeutics, Inc.'s stock price?
OnKure Therapeutics, Inc. (OKUR) trades at $2.41.
Is OnKure Therapeutics, Inc. overvalued?
OnKure Therapeutics, Inc. carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of OnKure Therapeutics, Inc. (OKUR)?
The 12-month analyst consensus target is $15.50, about 543.2% above the current $2.41. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
OnKure Therapeutics, Inc.'s Altman Z-Score is -1.25, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-31.87%
Beta0.75
50D MA$3.43
200D MA$3.65
Shares out0.04B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—